Genitourinary Syndrome of Menopause: Clinical Trials

6 trials for Genitourinary Syndrome of Menopause, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 not yet recruiting. 6 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 46Completed 5, Not yet recruiting 1

Follow Genitourinary Syndrome of Menopause: new trials by email Literature Review of Genitourinary Syndrome of Menopause trials Research Report on Genitourinary Syndrome of Menopause

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Difference in Serum Estrogen Level Based on Methods of Vaginal Estrogen Application (fingertip Vs Applicator Use) in Post-menopausal Women
application of the vaginal estrogen cream - Postmenopausal Atrophic Vaginitis, Genitourinary Syndrome of Menopause
Phase 4Not yet recruitingWalter Reed National Military Medical Center1102025-02-012025-02-05
Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit
Cellular Matrix / A-CP-HA Kit, Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel) - Genitourinary Syndrome of Menopause
Phase 4CompletedFundación Santiago Dexeus Font1922024-05-302026-09-21
Changes in Neighbouring Microbiota in Genitourinary Syndrome
Vaginal Cream with Applicator - Genitourinary Syndrome of Menopause
Phase 4CompletedKoc University Hospital312023-11-102024-10-09
Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders
Ospemifene 60 mg, fMRI experiments - Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause
Phase 4CompletedHospital Clinic of Barcelona252021-11-012025-09-15
Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women
vaginal estradiol 10 μg, vaginal DHEA 6.5 mg - Vulvovaginal Atrophy, Genitourinary Syndrome of Menopause
Phase 4CompletedAngelica Lindén Hirschberg1702020-12-182024-12-17
Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors
Prasterone (DHEA), Micronized - Vulvar Atrophy, Breast Cancer
Phase 4CompletedHospital Clinic of Barcelona102020-09-012022-02-22

Narrower conditions

Atrophic Vaginitis (1)  ·  Breast Neoplasms (1)  ·  Coitus (1)  ·  Sexual Dysfunction, Physiological (1)

Broader conditions

Genital Diseases (2)  ·  Urogenital Diseases (2)  ·  Behavior (1)  ·  Breast Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases, Female (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Sexual Behavior (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)  ·  Vaginal Diseases (1)  ·  Vaginitis (1)

Interventions

Dehydroepiandrosterone (1)  ·  Ospemifene (1)  ·  Vaginal Creams, Foams, and Jellies (1)

Sponsors

Hospital Clinic of Barcelona (2)  ·  Angelica Lindén Hirschberg (1)  ·  Fundación Santiago Dexeus Font (1)  ·  Koc University Hospital (1)  ·  Walter Reed National Military Medical Center (1)

Countries

Spain (3)  ·  Sweden (1)  ·  Turkey (Türkiye) (1)

Top investigators

Camil Castelo-Branco (2)

Results publications

PMID 41903372, PMID 42858690

NIH funding

2023 (1)